NCT05298592
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with untreated CNS metastases; Patients with central nervous system (CNS) metastases as the only site of active disease; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05298592